<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00196599</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 091 MONTANA</org_study_id>
    <nct_id>NCT00196599</nct_id>
  </id_info>
  <brief_title>Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults</brief_title>
  <official_title>Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Triangle Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dupont Applied Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <brief_summary>
    <textblock>
      In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple
      combination with protease inhibitor is recommended. Such therapy induces side effects and the
      number of pills may reduce therapy adherence. The aim of this study is to evaluate the
      efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with
      CD4 cell count over 100/mm3, antiretroviral naive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple
      combination with protease inhibitor is recommended. Side effects of this products and the
      number of pills may induce a lower adherence, and thus a lower efficacy. 40 patients with a
      CD4 count over 100/mm3, a HIV RNA over 5,000 copies/ml and antiretroviral naive, take the
      once daily combination of FTC, ddI, efavirenz during 24 weeks. The primary end-point is the
      viral success maintained from 12 weeks until 24 weeks. Secondary end-point is the adherence
      to the association and safety.

      The trial is prolonged during a total of 72 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date>September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological success</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 cell count</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of HIV infection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics criteria</measure>
  </secondary_outcome>
  <enrollment>39</enrollment>
  <condition>HIV Infections</condition>
  <condition>Antiretroviral Naive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine, FTC (drug)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>didanosine, ddI (drug)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Antiretroviral naive

          -  CD4 cell count over 100/mm3

          -  Plasma HIV RNA load over 5,000 copies/mL

               -  Signed written informed consent

        Exclusion Criteria:

          -  Hepatitis B infection

          -  Pregnancy

          -  Alcool abuse

          -  Acute infection, past neurological or pancreatic disease, biological abnormalities

          -  Chemotherapy or immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel Molina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Maladies Infectieuses, Hôpital Saint-Louis, Paris, 75475, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Genevieve Chene, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>INSERM unité 593, Bordeaux, France</affiliation>
  </overall_official>
  <results_reference>
    <citation>Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM, Chêne G. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000 Aug;182(2):599-602. Epub 2000 Jul 13.</citation>
    <PMID>10915095</PMID>
  </results_reference>
  <results_reference>
    <citation>Molina JM, Peytavin G, Perusat S, Lascoux-Combes C, Sereni D, Rozenbaum W, Chene G. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med. 2004 Mar;5(2):99-104.</citation>
    <PMID>15012649</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2005</last_update_posted>
  <keyword>HIV infections</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

